The HR using quetiapine treatment as the reference showed that the likelihood of reaching remission was numerically slightly higher with RLAI (1.18; 95% confidence interval [CI] 0.94–1.49). The Kaplan–Meier estimate of mean ± SE time to full remission was 422.6 ± 14.3 days with RLAI and 457.5 ± 16.5 days with quetiapine. Mean ± SD duration of full remission was 540.8 ± 181.4 days with RLAI and 508.1 ± 188.0 days with quetiapine. This numerical difference was not significant. Figure 1. Percentage of patients

in full remission by treatment month, starting Inhibitors,research,lifescience,medical at month 6. Figure 2. Kaplan–Meier plot of time to full remission. Log-rank test: p = 0.143. Time to full remission was also evaluated in patients who completed the full 24 months of

the study (n = 151 RLAI and n = 120 quetiapine). Among these patients, remission severity criteria were met at baseline by 55/151 patients ARRY-162 supplier treated with RLAI for 2 years and 34/120 patients with Inhibitors,research,lifescience,medical quetiapine for 2 years (36.4% versus 28.3%, p = 0.1929). Full remission criteria were met during the trial for 114/151 patients treated with RLAI for 2 years and 79/120 patients with Inhibitors,research,lifescience,medical quetiapine for 2 years (75.5% versus 65.8%, p = 0.1048). At endpoint, 101/151 patients receiving RLAI for 2 years (66.9%) and 72/120 patients receiving quetiapine for 2 years (60.0%) were in remission. Among this sample, the relative risk for reaching remission was similar between RLAI and quetiapine (HR 1.312, 95% CI 0.984–1.750). Secondary efficacy outcomes Inhibitors,research,lifescience,medical Endpoint changes in MADRS total and individual symptom scores and CGI-C are shown in Table 1. Improvements

in each measure favoured RLAI, except for MADRS-reported sadness. According to CGI-C, at endpoint 86 RLAI patients (26.4%) and 64 quetiapine patients (19.7%) were improved, with 37 RLAI (11.3%) and 22 quetiapine (6.8%) patients ‘much’ or ‘very much’ improved. Table 1. Endpoint changes in secondary efficacy measures. Safety and tolerability Safety data were available for all patients (329 RLAI and 337 quetiapine). TEAEs occurred similarly between treatment groups, Inhibitors,research,lifescience,medical most commonly psychiatric symptoms (43.2% of patients with RLAI and 43.0% with quetiapine) and nervous system disorders (18.8% with RLAI and 27.6% with quetiapine). Somnolence occurred in 11.3% of patients with quetiapine and 1.8% with RLAI. Death occurred in three patients Dipeptidyl peptidase treated with RLAI (two patients committed suicide and one had deep-vein thrombosis and peptic ulcer perforation) and two patients with quetiapine (one suicide and one myocardial infarction). None of the deaths was considered to be possibly or probably related to study drug by the principal investigator. Discussion Patients with clinically stable schizophrenia or schizoaffective disorder who switched to RLAI had a greater occurrence of sustained remission than those who switched to quetiapine. Remission was achieved by 51% of patients treated with RLAI compared with 39% receiving quetiapine (p = 0.003).